MapLight Initiates IPO to Compete with Bristol Myers’ Schizophrenia Medication

MapLight Initiates IPO to Compete with Bristol Myers’ Schizophrenia Medication

MapLight Initiates IPO to Compete with Bristol Myers’ Schizophrenia Medication